Traders purchased shares of Biogen Inc. (NASDAQ:BIIB) on weakness during trading hours on Thursday. $180.85 million flowed into the stock on the tick-up and $165.59 million flowed out of the stock on the tick-down, for a money net flow of $15.26 million into the stock. Of all companies tracked, Biogen had the 14th highest net in-flow for the day. Biogen traded down ($6.78) for the day and closed at $314.56

Several analysts have commented on the company. Jefferies Group reissued a “buy” rating and issued a $319.00 price objective on shares of Biogen in a report on Thursday. Citigroup Inc. reissued a “buy” rating and issued a $345.00 price objective on shares of Biogen in a report on Monday, April 11th. Standpoint Research lowered Biogen from a “buy” rating to a “hold” rating in a report on Tuesday. Leerink Swann reissued a “market perform” rating and issued a $319.00 price objective on shares of Biogen in a report on Wednesday, June 1st. Finally, Robert W. Baird reissued a “hold” rating on shares of Biogen in a report on Monday, May 16th. Ten analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $342.74.

The firm’s 50 day moving average price is $263.64 and its 200 day moving average price is $264.54. The stock has a market capitalization of $69.23 billion and a price-to-earnings ratio of 18.46.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Thursday, July 21st. The biotechnology company reported $5.21 earnings per share for the quarter, topping analysts’ consensus estimates of $4.69 by $0.52. During the same quarter in the prior year, the company earned $4.22 EPS. The firm earned $2.89 billion during the quarter, compared to analyst estimates of $2.79 billion. The business’s revenue was up 11.7% on a year-over-year basis. Equities analysts predict that Biogen Inc. will post $19.98 EPS for the current fiscal year.

In other Biogen news, CEO George A. Scangos sold 842 shares of the stock in a transaction on Friday, June 3rd. The stock was sold at an average price of $290.00, for a total transaction of $244,180.00. Following the sale, the chief executive officer now owns 54,936 shares in the company, valued at approximately $15,931,440. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO George A. Scangos sold 3,855 shares of the stock in a transaction on Wednesday, June 1st. The shares were sold at an average price of $289.74, for a total value of $1,116,947.70. Following the sale, the chief executive officer now owns 56,265 shares in the company, valued at approximately $16,302,221.10. The disclosure for this sale can be found here.

A number of large investors recently made changes to their positions in the stock. BlackRock Investment Management LLC boosted its stake in shares of Biogen by 0.8% in the fourth quarter. BlackRock Investment Management LLC now owns 1,097,747 shares of the biotechnology company’s stock worth $336,295,000 after buying an additional 8,756 shares during the period. Westfield Capital Management Co. LP boosted its stake in shares of Biogen by 74,344.5% in the fourth quarter. Westfield Capital Management Co. LP now owns 513,667 shares of the biotechnology company’s stock worth $157,362,000 after buying an additional 512,977 shares during the period. Nicholas Co. Inc. WI boosted its stake in shares of Biogen by 25.0% in the fourth quarter. Nicholas Co. Inc. WI now owns 10,010 shares of the biotechnology company’s stock worth $3,066,000 after buying an additional 2,005 shares during the period. KBC Group NV boosted its stake in shares of Biogen by 6.3% in the fourth quarter. KBC Group NV now owns 91,597 shares of the biotechnology company’s stock worth $28,061,000 after buying an additional 5,427 shares during the period. Finally, State of Tennessee Treasury Department boosted its stake in shares of Biogen by 211.4% in the fourth quarter. State of Tennessee Treasury Department now owns 383,602 shares of the biotechnology company’s stock worth $117,516,000 after buying an additional 260,412 shares during the period.

Biogen Inc, formerly Biogen Idec Inc, is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.